Amgen (AMGN) reported a 4% rise in quarterly revenue, as pandemic restrictions eased reporting adjusted earnings per share for the quarter of $4.69, beating the average analyst forecast of $4.27. Amgen’s net earnings dropped 3% to $3.31 per share with a $400 million licensing-related expense from a collaboration with Japan’s Kyowa Kirin Co Ltd.
Revenue for the quarter stood at $6.7 billion, up from $6.4 billion a year earlier, and in line with analyst expectations. Sales volume for the quarter increased 8%, but net selling prices fell 7% as competition, including from cheaper generics and biosimilars, lowered prices for its migraine, arthritis, and infection-fighting drugs. Sales of arthritis drug Enbrel also decreased 3% from a year earlier to $1.29 billion. Sales of newer cancer drug Lumakras reported $36 million for the quarter, exceeding analyst estimates of $28 million.
Full-year stock buybacks will come in near the high end of the company’s estimated range of $3 billion to $5 billion, informed Chief Financial Officer Peter Griffith. For the full year, Amgen lowered the top end of its revenue forecast to $26.2 billion from a previous $26.6 billion. It also slightly raised its outlook for 2021 adjusted earnings per share to between $16.50 and $17.10 from a previous range of $16.00 to $17.00.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
